Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Acorda Therapeutics Inc (ACOR)  
$0.50 0.00 (0.00%) as of 4:30 Fri 6/2


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 47,962,000
Market Cap: 24.08(M)
Last Volume: 12,631,282 Avg Vol: 9,790,299
52 Week Range: $0.465 - $0.88
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of episodic motor fluctuations, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija utilizes Co.'s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Co. also markets Ampyra (dalfampridine) extended release tablets, 10 mg for improving walking in patients with multiple sclerosis. Ampyra is marketed as Fampyra outside the U.S.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 20,156
Total Buy Value $0 $0 $0 $12,594
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 2
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 610
  Page 8 of 25  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Sabella Lauren M Chief Commercial Officer   •       –      –    2017-12-01 4 AS $20.53 $34,289 D/D (1,670) 14,679     -
   Wasman Jane President, Intl and GC   •       –      –    2017-12-01 4 AS $20.52 $93,662 D/D (4,564) 102,110     -
   Blank Burkhard Chief Medical Officer   •       –      –    2017-12-01 4 AS $20.53 $226,893 D/D (11,050) 33,150     -
   Lawrence David Chief, Bus. Ops & PAO   •       –      –    2017-12-01 4 AS $20.51 $81,885 D/D (3,993) 4,693     -
   Lawrence David Chief, Bus. Ops & PAO   •       –      –    2017-10-09 4 AS $25.40 $6,350 D/D (250) 8,686     -
   Mindich Jeremy 10% Owner   –       –       •   2017-08-29 4 B $19.05 $14,730,449 I/I 766,201 8,474,728 1.5     -
   Greene Barry E Director   –       •      –    2017-08-01 4 AS $21.57 $215,697 D/D (10,000) 0     -
   Greene Barry E Director   –       •      –    2017-08-01 4 OE $18.21 $182,100 D/D 10,000 10,000     -
   Rauscher Steven M Director   –       •      –    2017-08-01 4 AS $21.57 $215,703 D/D (10,000) 0     -
   Rauscher Steven M Director   –       •      –    2017-08-01 4 OE $18.21 $182,100 D/D 10,000 10,000     -
   Randall Lorin Director   –       •      –    2017-07-31 4 S $21.66 $216,615 D/D (10,000) 0     -
   Randall Lorin Director   –       •      –    2017-07-31 4 OE $18.21 $182,100 D/D 10,000 10,000     -
   Cohen Ron President and CEO   •       •      –    2017-06-16 4 B $16.95 $338,998 D/D 20,000 511,648 2.81     -
   Hindman Andrew A. Chief Business Dev. Officer   •       –      –    2017-05-15 4 AS $15.75 $121,319 D/D (7,704) 46,123     -
   Wasman Jane President, Intl and GC   •       –      –    2017-03-01 4 A $0.00 $0 D/D 5,000 106,674     -
   Blank Burkhard Chief Medical Officer   •       –      –    2017-03-01 4 A $0.00 $0 D/D 4,200 44,200     -
   Lawrence David Chief, Bus. Ops & PAO   •       –      –    2017-02-09 4 AS $22.32 $1,410,542 D/D (63,183) 4,536     -
   Lawrence David Chief, Bus. Ops & PAO   •       –      –    2017-02-09 4 OE $22.13 $1,398,240 D/D 63,183 67,719     -
   Wasman Jane President, Intl and GC   •       –      –    2017-02-09 4 AS $22.30 $1,216,218 D/D (54,536) 101,674     -
   Wasman Jane President, Intl and GC   •       –      –    2017-02-09 4 OE $22.13 $1,206,882 D/D 54,536 156,210     -
   Blight Andrew Chief Scientific Officer   •       –      –    2017-02-09 4 AS $22.41 $1,514,379 D/D (67,586) 76,558     -
   Blight Andrew Chief Scientific Officer   •       –      –    2017-02-09 4 OE $22.13 $1,495,678 D/D 67,586 144,144     -
   Greene Barry E Director   –       •      –    2017-02-09 4 AS $22.65 $16,376 D/D (723) 0     -
   Greene Barry E Director   –       •      –    2017-02-09 4 OE $22.13 $16,000 D/D 723 723     -
   Greene Barry E Director   –       •      –    2017-01-03 4 AS $19.26 $58,113 D/D (3,017) 0     -

  610 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 25
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed